Overview
- TuneLab launches with 18 models: 12 for small-molecule property prediction and six for antibody developability.
- Training runs through Rhino Federated Computing using Nvidia technology so models learn from partner data without exposing proprietary datasets.
- About a dozen startups have joined, including Insitro, Circle Pharma, Firefly Bio and Superluminal Medicines, with Insitro set to build additional models for small-molecule discovery.
- The models draw on years of Lilly experiments, supported by more than $1 billion in investment and data from hundreds of thousands of unique molecules.
- Participation flows through Lilly’s Catalyze360 program, which offers capital, lab space, technology and expertise, and is limited to biotechs already in preclinical development with a small-molecule or antibody candidate.